Piramal Pharma Share Price Target 2030 Expert Forecast

For new investors, Piramal Pharma Limited represents a compelling entry point into India’s vibrant pharmaceutical sector. This article dissects the company’s latest performance, fundamentals, and expert forecasts, including 2030 and long-term share price targets with tables using the most recent 24-hour market data. Insights here will empower both seasoned and first-time buyers to navigate Piramal Pharma’s investment potential confidently.

Piramal Pharma Share Overview

Piramal Pharma Limited (PPL) was incorporated as a public company in March 2020, rapidly building a solid foundation in pharmaceuticals. Their diversified business model spans Contract Development and Manufacturing Organization (CDMO), the Consumer Healthcare Group (CHG), and India Consumer Healthcare (ICH). With 17 global facilities and an extensive distribution network reaching more than 100 countries, Piramal Pharma has become a prominent player both domestically and internationally.

Company Snapshot

• Market Capitalization: ₹27,075.46 Crore (as of Sep 16, 2025)
• Share Price (NSE/BSE): ₹204.90 / ₹204.00 (Sep 16, 2025)
• 52-Week Range: ₹181.73 – ₹307.90

Fundamental Analysis Of Piramal Pharma Share

Business Segments

• CDMO: Full-spectrum drug development and manufacturing—increasing demand globally.
• Regional Strengths: Strong in anti-infectives, self-care, and consumer brands like Saridon, Supradyn, Lacto Calamine.
• Strategic Partnerships: JV with Allergan (ophthalmology leader) and stakes in Yapan Bio (biologics, vaccines).

Last Few Years’ Performance Of Piramal Pharma Share

Financials At a Glance

• Performance Review: Sales have grown consistently, with a healthy jump through FY2025.
• Profitability: Net profits have fluctuated, mainly due to high R&D expenditure and aggressive capacity expansions.

Also Check: Hpe Share Price Target 2030: Guide for New Investors

Profit Growth

Piramal Pharma achieved a 5x increase in net profits for FY25, crossing ₹1,000 crore in annual revenues for the first time. Their focus on innovation, cost controls, and premium segment expansion have strengthened bottom-line growth, despite volatility in individual quarters.

Sales Growth

• FY2025: Sales increased by 12% year-on-year, with strong contributions from commercial manufacturing in the CDMO vertical.
• Latest Quarter (Q1FY26): Marginal decline of 1% YoY, attributed to cyclical demand and capacity investments.

ROE Percentage

• Return on Equity (ROE): 1.11% (FY2025)
• This figure, while modest, reflects the capital-intensive nature of pharma manufacturing, expected to improve as profitability stabilizes.

ROCE Percentage

• Return on Capital Employed (ROCE): 6.45% (FY2025)
• Indicative of efficient use of capital, mainly driven by CDMO’s robust cash flows.

Total Expenditure Amount

Piramal Pharma’s total expenditure rose by 3.5% YoY, a consequence of ongoing investments in research, expansion, and operational excellence initiatives. Employee costs make up 25.21% and interest expenses 4.61% of operating revenues for FY25.

The Net Cash Flow Amount

While detailed cash flow statements fluctuate quarterly, net-debt to EBITDA ratio improved to 2.7x in FY25, showcasing strong debt management and robust operational cash generation.

Total Assets Amount

Assets have grown consistently, supporting capacity expansion in high-growth segments like antibody-drug conjugates (ADCs) and biologics.

Piramal Pharma Share Price Targets

Below are consensus price targets sourced from both broker reports and algorithmic forecasts.

Note: 2030 price targets show large variance, reflecting both algorithmic (AI) pessimism and human analyst bullishness. Jefferies, Motilal Oswal, and ICICI Securities have all set 2030 target above ₹250, contingent on execution of the $2 billion revenue ambition.

Detailed Target Tables

Is Piramal Pharma Share Good to Buy?

Current Valuation

• PE Ratio: 37.64 (Sector Average: 39.85)
• PB Ratio: 3.62
• Overvalued according to intrinsic value models; may not be the best short-term buy for value-focused investors as of Sep 2025.

For Long-Term Investors

• If Piramal’s $2 billion revenue and EBITDA margin expansion plan succeeds, significant upside is possible. Mutual funds hold 12.32%, suggesting institution interest is strong.

Factors Influencing Piramal Pharma Share

• Industry Growth: Global pharma demand driven by aging population, chronic illnesses, and biologics innovation.
• Regulatory Approvals: USFDA, EMA, and other international certifications drive exports.
• Acquisitions & Partnerships: Recent deals include Convergence Chemicals and Hemmo Pharmaceuticals (for peptide APIs).
• Investments: Capacity expansion in high-margin sectors like ADCs and hospital generics.
• Competition: Intense pricing and technological innovation in the pharma sector.

Key Competitors of Piramal Pharma Share

Expert Forecasts on the Future of Piramal Pharma

Bull Case:

• Revenue to double and EBITDA margins to triple to 25% by 2030.
• Strong CDMO pipeline and differentiation in antibody-drug conjugates.
• Record of zero regulatory observations and industry-leading ESG scores.
• Potential for re-rating as global pharma demand surges and Piramal achieves its $2B ambition.

Bear Case:

• AI-based price models project a decline under pessimistic scenarios, with forecasts as low as ₹77 by 2030.
• Risk factors: Global patent cliffs, cost overruns, regulatory hurdles, or slower growth in consumer health could pressure margins.
• Overvaluation warnings from several intrinsic valuation models as of Sep 2025.

Step-by-Step Guide: How to Buy Piramal Pharma Shares

1. Open a Demat Account: Choose a broker (e.g., Kotak Securities, Zerodha, Groww) and complete KYC.
2. Fund Your Account: Transfer required investment funds.
3. Search for Piramal Pharma (NSE: PPLPHARMA, BSE: 543635):
4. Place Buy Order: Decide on quantity and place a market or limit order.
5. Monitor Holdings: Track performance and news for further decisions.

Frequently Asked Questions (FAQs)

Q1: What is Piramal Pharma’s current share price?
A: As of Sep 16, 2025 – ₹204.90 (NSE) / ₹204.00 (BSE), market cap ₹27,075.46 Cr.

Q2: What is the 2030 price target for Piramal Pharma?
A: Analyst targets ₹250–₹300, while algorithmic projections range ₹77–₹100; dependent on execution of growth strategy.

Q3: Is Piramal Pharma good for beginners?
A: Yes, due to diversified segments and robust institutional backing, but entry at current valuations may require patience.

Q4: Who are Piramal Pharma’s key competitors?
A: Sun Pharma, Divi’s Labs, Cipla, Torrent Pharma.

Q5: Is Piramal Pharma overvalued?
A: Some intrinsic models say yes, but this may change as execution improves.

Conclusion

Piramal Pharma stands at an inflection point: with ambitious leadership aiming for $2 billion revenue by 2030, robust CDMO operations, and strategic partnerships, its growth prospects are bright. However, investors—especially newcomers—should weigh valuation risks and monitor execution closely. For those willing to ride the wave of India’s pharmaceutical boom, Piramal Pharma could be a smart long-term bet, especially if acquired during market corrections.